Opendata, web and dolomites

METMEL SIGNED

Long range-acting drivers of premetastatic niches in melanoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 METMEL project word cloud

Explore the words cloud of the METMEL project. It provides you a very rough idea of what is the project "METMEL" about.

invasive    clinically    pending    indicators    whereby    inherent    unclear    relevance    distal    secretome    ge    lesions    lymphoreporter    melanomas    lymphovascular    secreted    biomarkers    subsequently    oncologist    thin    performed    progression    interactions    imaging    acting    lymph    novelty    rising    dynamic    niche    drive    physiological    body    stages    immune    cancer    rates    occurs    prognostic    demonstrated    models    ranking    incidence    ultimately    genes    treatments    filtered    mouse    questions    soengas    lymphoreporters    succumb    proteomic    nodes    risk    components    underlying    favouring    sites    cells    dermatologists    lymphangiogenesis    seemingly    tumour    primary    melanoma    pathologists    world    metastasis    neo    group    mm    bear    draining    lymphatic    disease    permissive    crosstalk    vasculature    patients    proteins    mechanisms    fastest    proximal    metastatic    link    fraction    screening    induce    newly    unprecedented    secondly    therapies   

Project "METMEL" data sheet

The following table provides information about the project.

Coordinator
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 

Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029
website: www.cnio.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2020-07-16

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III ES (MADRID) coordinator 170˙121.00

Map

 Project objective

Melanoma is the cancer with the fastest rising incidence world-wide, and although recent therapies can achieve unprecedented response rates, a significant fraction of patients still succumb to metastatic lesions. Key pending questions in the field are the mechanisms underlying the inherent metastatic behaviour or melanoma, whereby seemingly thin primary lesions (≥2 mm in depth) bear high risk of dissemination to proximal lymph nodes and ultimately, to distal sites. A dynamic crosstalk has been proposed to be established between melanoma cells and the lymphatic vasculature at tumour-draining lymph nodes, favouring an immune-permissive “lymphovascular niche”. However, whether (and how) these lymphovascular interactions occur at distal sites is unclear. The Soengas group has generated unique “Lymphoreporter” melanoma mouse models for non-invasive and whole body imaging of tumour progression. These lymphoreporters demonstrated that primary melanomas induce neo-lymphangiogenesis at distal pre-metastatic sites, already from very early stages of the disease, before dissemination occurs. Proteomic analyses were then performed to identify factors in the melanoma secretome that could drive these long range-acting effects and subsequently filtered these proteins for novelty (i.e. no previous link to melanoma and lymphangiogenesis). Here I will focus on the top-ranking factors in this screening. In particular, I will define the impact of these newly-identified melanoma secreted factors on tumour progression and metastasis, focusing on key components of the lymphovascular niche (i.e. on the crosstalk of tumour- vasculature-immune system). Secondly, I will assess the impact of these genes as prognostic biomarkers and indicators of response to clinically-relevant treatments. These studies will be performed in collaboration with dermatologists, pathologists and oncologist to define the physiological relevance of our work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METMEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METMEL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

COLEX (2019)

Coopetition and Legislation in the Spanish Netherlands (1598-1665)

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More